Profile data is unavailable for this security.
About the company
Mural Oncology plc is a clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
- Revenue in USD (TTM)0.00
- Net income in USD-191.90m
- Incorporated2017
- Employees117.00
- LocationMural Oncology PLC10 Earlsfort TerraceDUBLIN D02 T380IrelandIRL
- Phone+353 19058020
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kronos Bio Inc | 7.59m | -116.39m | 61.30m | 61.00 | -- | 0.4475 | -- | 8.08 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Avrobio Inc | 0.00 | 30.31m | 61.95m | 13.00 | 2.00 | 0.6972 | 2.02 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 63.17m | 8.00 | -- | 0.7775 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Curis Inc | 9.81m | -47.73m | 63.63m | 48.00 | -- | 6.72 | -- | 6.48 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -191.90m | 63.80m | 117.00 | -- | 0.2716 | -- | -- | -11.49 | -11.49 | 0.00 | 13.88 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 64.09m | 230.00 | -- | -- | -- | 1.30 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
| Aeon Biopharma Inc | 0.00 | -485.01m | 64.55m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -66.03m | 64.58m | 41.00 | -- | 0.5837 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Turnstone Biologics Corp | 0.00 | -74.92m | 64.99m | 82.00 | -- | 0.8123 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -22.12m | 65.45m | 31.00 | -- | 1.54 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Celularity Inc | 14.79m | -181.41m | 65.78m | 225.00 | -- | 1.93 | -- | 4.45 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -15.13m | 66.37m | 5.00 | -- | 6.83 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Ikena Oncology Inc | 3.85m | -70.09m | 66.60m | 34.00 | -- | 0.4287 | -- | 17.31 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Rallybio Corp | 0.00 | -76.28m | 66.73m | 43.00 | -- | 0.6828 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Data as of May 21 2024. Currency figures normalised to Mural Oncology PLC's reporting currency: US Dollar USD
53.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 1.66m | 9.80% |
| Westfield Capital Management Co. LPas of 30 Apr 2024 | 1.32m | 7.80% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.01m | 5.95% |
| DUMAC, Inc.as of 01 Apr 2024 | 1.00m | 5.93% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 920.47k | 5.44% |
| Verition Fund Management LLCas of 31 Mar 2024 | 792.47k | 4.68% |
| Solas Capital Management LLCas of 31 Mar 2024 | 748.96k | 4.43% |
| Alta Fundamental Advisers LLCas of 31 Mar 2024 | 723.26k | 4.27% |
| Newtyn Management LLCas of 31 Mar 2024 | 500.00k | 2.96% |
| Prosight Management LPas of 31 Mar 2024 | 400.00k | 2.36% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
